NCT02645734

The Effect of Bevacizumab and Ziv-aflibercept in Diabetic Macular Edema

The Comparison Between the Therapeutic Effect of Intravitreal Bevacizumab and Ziv-aflibercept in Diabetic Macular Edema

• Status: Unknown
• Phase: Phase 2 / Phase 3
• Study type: Interventional
• Enrollment: 133 (estimated)
• Sponsor: Shahid Beheshti University of Medical Sciences · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Accepted

Summary

In this double clinical trial 132 patient with the history of DME (Diabetic Macular Edema) to receive intravitreous bevacizumab at a dose of 1.25mg (44 patient) , ziv-aflibercept at dose of 1.25 mg (44 patient) , ziv-aflibercept at dose of 2.5 mg (44 patient) . The study drugs were administered as often as every 4 weeks for 3 months.monitoring of best-corrected visual acuity, CST ( Central Subfield Thickness) by OCT (Optical coherence tomography) was done from base line ,4 weeks, 8weeks after injection.

Conditions

• Diabetic Macular Edema

Interventions

Type	Name	Description
DRUG	bevacizumab	1.25 mg of bevacizumab is injected
DRUG	ziv-aflibercept 1.25 mg	1.25 mg of ziv-aflibercept is injected
DRUG	ziv-aflibercept 2.5mg	2.5 mg of ziv-aflibercept is injected

Timeline

• Primary completion: 2016-02-01
• First posted: 2016-01-05
• Last updated: 2016-01-05

Locations

1 site across 1 country: Iran